Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic umbilical cord-derived mesenchymal stem cells (Prodia Stem Cell Indonesia)
- Development stage
- Unknown
- Lead developer
- Prodia Stem Cell Indonesia
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intracoronary
01
Overview
This investigational cell therapy, developed by PT. Prodia Stem Cell Indonesia (ProSTEM), consists of allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) isolated from Wharton's Jelly of umbilical cord tissue. It is currently being evaluated in Phase 1/2 clinical trials for the treatment of acute myocardial infarction (AMI), specifically in patients with ST-elevation myocardial infarction (STEMI) who have undergone percutaneous coronary intervention (PCI). The therapy is designed to facilitate cardiac tissue regeneration and repair by reducing inflammation, promoting angiogenesis, and potentially differentiating into cardiac-like cells. Early clinical results have indicated improvements in Left Ventricular Ejection Fraction (LVEF) and functional capacity as measured by the 6-Minute Walk Test, with a favorable safety profile.
- Other names
- UC-MSCsumbilical cord-derived mesenchymal stem cellsallogeneic UC-MSCsWharton's Jelly-derived mesenchymal stem cells
Beyond the preview
Go deeper on allogeneic umbilical cord-derived mesenchymal stem cells (Prodia Stem Cell Indonesia).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic umbilical cord-derived mesenchymal stem cells (Prodia Stem Cell Indonesia).